ArticleBMC medical genomics2026
Association of TP53 polymorphic variants rs1042522 and rs1642785 with susceptibility and prognosis of acute lymphoblastic leukemia in a Brazilian Amazon population.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTumor suppressor genes play a central role in cancer development, and inherited genetic variation may influence both disease susceptibility and clinical outcomes. This study aimed to investigate the frequency and prognostic relevance of TP53 polymorphic variants in patients with acute lymphoblastic leukemia (ALL) from an admixed population in the Brazilian Amazon.
methodsA population-based case–control study was conducted including 193 patients diagnosed with ALL and 215 healthy controls. Germline TP53 polymorphisms rs1042522 and rs1642785 were genotyped, and allele and genotype frequencies were compared between groups. Associations with ALL susceptibility, relapse, and mortality were evaluated using multiple genetic models adjusted for age and sex. Combined genotype and haplotype analyses were performed, and overall survival was estimated using Kaplan-Meier curves and log-rank tests.
resultsThe CC genotype and the allele C were more frequent among ALL cases than controls. The allele C of rs1042522 (p = 0.021) and rs1642785 (p = 0.022) was associated with increased susceptibility to ALL. In addition, the allele C of rs1042522 was associated with a higher risk of relapse (p = 0.016) and death (p = 0.009). Protective effects against ALL were observed under the recessive model for rs1042522 (p = 0.019) and the codominant model for rs1642785 (p = 0.013). Both variants showed protective associations with mortality under the log-additive model. Combined genotype analysis revealed that the CG and GG genotypes of rs1042522 were associated with a reduced risk of relapse (p < 0.001). Overall survival analysis showed reduced survival associated with the CC genotype, whereas improved survival was observed for the heterozygous CG genotype. Haplotype analysis indicated that the GG haplotype was associated with a reduced risk of ALL (p = 0.007) and death (p = 0.013).
conclusionsOur findings suggest that germline TP53 variants rs1042522 and rs1642785 modulate susceptibility and clinical outcomes in ALL, supporting their potential role as prognostic biomarkers. This study highlights the importance of population-based genomic investigations in underrepresented populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.